Molecular-targeted therapies against alterations in several oncogenic driver genes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS Proto-Oncogene 1 (ROS1, a receptor tyrosine kinase), have significantly improved the prognosis of cancer patients harboring these gene mutations [2, 3]. The gene discussed is ALK; the disease is cancer.